Cardinal Health, Inc. (CAH) Key Metrics
CAH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $58.83B
- Enterprise value
- $55.27B
- P/E (TTM)
- 35.1 10-yr median 28.0
- Forward P/E
- 17.7
- PEG ratio
- 1.11
- Price / sales
- 0.2 10-yr median 0.1
- Price / book
- 16.1 10-yr median 3.7
- EV / EBITDA
- 15.9 10-yr median 15.6
- Dividend yield
- 0.81% $2.06 a year
- Beta
- 0.50
CAH key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsCAH valuation Price multiples at each fiscal year-end price.
CAH returns How much profit the business earns on the capital it uses.
CAH per-share figures Results divided by the shares outstanding at year-end.
CAH financial health Debt, liquidity and how easily interest is covered.
CAH efficiency & capital use Working capital cycle and where the cash goes.
CAH valuation history
CAH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CAH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CAH cash returned to shareholders
CAH price vs earnings per share
CAH key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $56.30B | $40.66B | $24.29B | $24.78B | $14.58B | $16.78B | $15.29B | $14.18B | $15.38B | $24.93B |
| Enterprise value | $61.39B | $46.13B | $24.76B | $25.88B | $15.67B | $20.09B | $19.30B | $19.68B | $22.63B | $28.45B |
| P/E ratio | 32.8 | 26.0 | 28.5 | 75.1 | — | 27.5 | — | 10.4 | 60.1 | 19.4 |
| Price / sales | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
| Price / book | — | — | — | — | — | 9.4 | 8.5 | 2.2 | 2.5 | 3.7 |
| Price / free cash flow | 12.4 | 22.0 | 7.5 | 10.5 | 5.3 | 8.3 | 9.6 | 5.9 | 6.5 | 31.3 |
| Price / operating cash flow | 10.9 | 17.0 | 6.5 | 8.7 | 4.7 | 6.9 | 7.8 | 5.2 | 5.6 | 21.1 |
| EV / sales | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 |
| EV / EBITDA | 17.7 | 14.9 | 12.6 | 18.0 | 284.9 | 15.6 | — | 6.5 | 20.0 | 10.0 |
| EV / free cash flow | 13.6 | 24.9 | 7.6 | 11.0 | 5.7 | 9.9 | 12.2 | 8.2 | 9.5 | 35.7 |
| Earnings yield | 3.0% | 3.8% | 3.5% | 1.3% | −6.4% | 3.6% | −24.2% | 9.6% | 1.7% | 5.2% |
| Free cash flow yield | 8.0% | 4.6% | 13.4% | 9.5% | 18.8% | 12.1% | 10.4% | 16.9% | 15.5% | 3.2% |
| Dividend yield | 0.9% | 1.2% | 2.1% | 2.1% | 3.8% | 3.4% | 3.7% | 4.1% | 3.8% | 2.3% |
| Shareholder yield (dividends + buybacks) | 3.3% | 3.1% | 5.1% | 10.2% | 10.7% | 4.6% | 6.0% | 8.3% | 7.4% | 4.7% |
| Share price at fiscal year-end | $237.56 | $168.00 | $98.32 | $94.57 | $52.27 | $57.09 | $52.19 | $47.10 | $48.83 | $77.92 |
| Per share | ||||||||||
| Revenue per share | $1,072.78 | $919.74 | $918.33 | $782.36 | $649.91 | $552.61 | $521.92 | $483.50 | $434.31 | $406.18 |
| Earnings per share | $7.23 | $6.45 | $3.45 | $1.26 | −$3.36 | $2.08 | −$12.60 | $4.53 | $0.81 | $4.03 |
| Operating cash flow per share | $21.83 | $9.90 | $15.23 | $10.84 | $11.19 | $8.26 | $6.69 | $9.04 | $8.79 | $3.70 |
| Free cash flow per share | $19.09 | $7.64 | $13.16 | $9.00 | $9.80 | $6.90 | $5.41 | $7.95 | $7.57 | $2.49 |
| Cash per share | $20.49 | $16.01 | $20.78 | $15.56 | $16.91 | $11.59 | $9.46 | $8.41 | $5.60 | $21.50 |
| Book value per share | −$12.16 | −$11.49 | −$13.01 | −$11.29 | −$2.54 | $6.09 | $6.11 | $21.02 | $19.23 | $21.27 |
| Tangible book value per share | −$69.68 | −$61.81 | −$39.12 | −$34.52 | −$29.89 | −$28.24 | −$32.38 | −$18.21 | −$19.59 | −$7.50 |
| Dividends per share | $2.07 | $2.04 | $2.02 | $2.00 | $2.00 | $1.95 | $1.94 | $1.92 | $1.84 | $1.80 |
| Capex per share | $2.74 | $2.26 | $2.07 | $1.84 | $1.39 | $1.36 | $1.28 | $1.09 | $1.22 | $1.21 |
| Debt per share | $41.97 | $38.62 | $22.71 | $19.76 | $20.81 | $22.84 | $23.12 | $26.68 | $28.61 | $32.48 |
| Shares outstanding | 237.0M | 242.0M | 247.0M | 262.0M | 279.0M | 294.0M | 293.0M | 301.0M | 315.0M | 320.0M |
| Change in shares outstanding | −2.1% | −2.0% | −5.7% | −6.1% | −5.1% | +0.3% | −2.7% | −4.4% | −1.6% | −3.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | — | 34.1% | −91.0% | 22.0% | 4.0% | 19.3% |
| Return on invested capital (ROIC) | 83.7% | — | — | — | −17.5% | 8.7% | −36.7% | 12.8% | 0.8% | 14.2% |
| Return on assets (ROA) | 3.1% | 3.2% | 1.9% | 0.8% | −2.1% | 1.4% | −9.0% | 3.4% | 0.6% | 3.5% |
| Return on tangible assets | 3.9% | 3.8% | 2.2% | 0.9% | −2.6% | 1.8% | −12.5% | 4.7% | 0.9% | 4.2% |
| Free cash flow margin | 1.8% | 0.8% | 1.4% | 1.2% | 1.5% | 1.2% | 1.0% | 1.6% | 1.7% | 0.6% |
| Income quality (OCF / net income) | 3.02 | 1.54 | 4.42 | 8.60 | — | 3.98 | — | 2.00 | 10.81 | 0.92 |
| Financial health | ||||||||||
| Total debt | $9.95B | $9.35B | $5.61B | $5.18B | $5.80B | $6.71B | $6.78B | $8.03B | $9.01B | $10.39B |
| Cash & short-term investments | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B |
| Net debt | $5.09B | $5.47B | $476.0M | $1.10B | $1.09B | $3.31B | $4.00B | $5.50B | $7.25B | $3.52B |
| Debt / equity | — | — | — | — | — | 3.75 | 3.79 | 1.27 | 1.49 | 1.53 |
| Debt / assets | 0.17 | 0.18 | 0.12 | 0.12 | 0.13 | 0.15 | 0.17 | 0.20 | 0.23 | 0.26 |
| Net debt / EBITDA | 1.46 | 1.76 | 0.24 | 0.76 | 19.78 | 2.57 | — | 1.81 | 6.40 | 1.24 |
| Current ratio | 0.88 | 0.94 | 0.98 | 1.00 | 1.08 | 1.12 | 1.10 | 1.07 | 1.07 | 1.34 |
| Quick ratio | 0.49 | 0.50 | 0.56 | 0.52 | 0.57 | 0.60 | 0.54 | 0.54 | 0.53 | 0.80 |
| Interest coverage | 7.5 | 10.6 | 24.4 | 9.0 | -4.1 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 |
| Working capital | −$5.15B | −$2.52B | −$756.0M | −$3.0M | $2.38B | $3.42B | $2.33B | $1.64B | $1.66B | $7.12B |
| Invested capital | $2.21B | $2.69B | −$2.74B | −$1.86B | $379.0M | $5.10B | $5.79B | $11.83B | $13.31B | $10.32B |
| Tangible asset value | −$16.36B | −$14.81B | −$9.66B | −$9.04B | −$8.34B | −$8.30B | −$9.48B | −$5.48B | −$6.17B | −$2.38B |
| Net current asset value | −$21.27B | −$19.38B | −$13.45B | −$12.57B | −$11.65B | −$11.61B | −$13.03B | −$8.89B | −$9.34B | −$4.94B |
| Graham number | — | — | — | — | — | $16.88 | — | $46.28 | $18.75 | $43.89 |
| Graham net-net per share | −$152.56 | −$138.57 | −$107.93 | −$98.62 | −$86.45 | −$85.47 | −$79.88 | −$64.30 | −$63.89 | −$46.00 |
| Capital allocation | ||||||||||
| Dividends paid | $491.0M | $494.0M | $499.0M | $525.0M | $559.0M | $573.0M | $569.0M | $577.0M | $581.0M | $577.0M |
| Share buybacks (net) | $1.36B | $765.0M | $750.0M | $2.00B | $1.00B | $200.0M | $350.0M | $600.0M | $550.0M | $600.0M |
| Dividend payout ratio | 28.6% | 31.6% | 58.6% | 159.1% | — | 93.8% | — | 42.3% | 227.0% | 44.8% |
| Dividends + buybacks / free cash flow | 40.9% | 68.1% | 38.4% | 107.1% | 57.0% | 38.1% | 58.0% | 49.2% | 47.4% | 147.7% |
| Capex / revenue | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% |
| Capex / operating cash flow | 12.5% | 22.8% | 13.6% | 16.9% | 12.4% | 16.5% | 19.1% | 12.0% | 13.9% | 32.7% |
| Capex / depreciation | 0.68 | 0.69 | 0.72 | 0.70 | 0.56 | 0.51 | 0.41 | 0.33 | 0.37 | 0.54 |
| Stock-based compensation / revenue | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| SG&A / revenue | 2.4% | 2.4% | 2.2% | 2.4% | 2.5% | 2.8% | 3.0% | 3.1% | 3.4% | 2.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 19.4 | 20.8 | 18.7 | 19.3 | 19.8 | 19.5 | 19.9 | 20.4 | 21.1 | 21.7 |
| Days of inventory on hand | 25.5 | 27.1 | 25.8 | 29.3 | 31.6 | 32.6 | 32.5 | 33.1 | 33.2 | 32.4 |
| Days payables outstanding | 54.5 | 56.6 | 51.3 | 52.6 | 53.1 | 52.8 | 53.6 | 54.2 | 52.9 | 52.1 |
| Cash conversion cycle (days) | -9.6 | -8.8 | -6.8 | -4.0 | -1.7 | -0.7 | -1.2 | -0.8 | 1.5 | 2.0 |
| Receivables turnover | 18.79 | 17.58 | 19.56 | 18.91 | 18.43 | 18.71 | 18.30 | 17.91 | 17.27 | 16.82 |
| Payables turnover | 6.70 | 6.45 | 7.11 | 6.94 | 6.88 | 6.91 | 6.81 | 6.73 | 6.90 | 7.01 |
| Inventory turnover | 14.33 | 13.49 | 14.12 | 12.48 | 11.57 | 11.20 | 11.23 | 11.04 | 10.98 | 11.26 |
| Asset turnover | 4.61 | 4.53 | 5.13 | 4.70 | 4.11 | 3.81 | 3.74 | 3.60 | 3.42 | 3.50 |
| Average receivables | $13.53B | $12.66B | $11.60B | $10.84B | $9.84B | $8.68B | $8.36B | $8.12B | $7.92B | $7.73B |
| Average payables | $36.50B | $33.24B | $30.85B | $28.53B | $25.41B | $22.54B | $21.45B | $20.61B | $18.79B | $17.61B |
| Average inventory | $17.06B | $15.89B | $15.54B | $15.88B | $15.12B | $13.90B | $13.01B | $12.56B | $11.80B | $10.96B |
| Intangibles / total assets | 23.8% | 22.9% | 14.3% | 14.0% | 17.4% | 22.7% | 27.7% | 28.8% | 30.6% | 23.0% |
Computed from CAH's annual financial statements (latest annual report filed August 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CAH valuation and financial ratios
At the end of fiscal 2026 (June 30, 2026), Cardinal Health traded at 32.8 times earnings, against a 10-year median of 28.0. Based on the latest twelve months, the trailing P/E is 35.1 and the forward P/E is 17.7. Cardinal Health earned a return on invested capital of 83.7% in fiscal 2026. It ended the year with $9.9 billion of debt and $4.9 billion in cash and short-term investments, net debt of $5.1 billion. It returned $1.8 billion to shareholders: $491.0 million in dividends and $1.4 billion in share buybacks, 41% of free cash flow. The share count fell 25.9% from 320.0M to 237.0M over 9 years.
See the CAH income statement, the CAH chart for price history, or the CAH stock overview for the latest quote and news.
CAH key metrics FAQ
What is Cardinal Health's P/E ratio?
Cardinal Health's trailing P/E ratio is 35.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 17.7. At the end of fiscal 2026 it was 32.8, compared with a 10-year median of 28.0.
What is Cardinal Health's EV/EBITDA?
Cardinal Health's enterprise value was 17.7 times EBITDA at the end of fiscal 2026 (enterprise value $61.4 billion, EBITDA $3.5 billion); the current EV/EBITDA is 15.9.
What is Cardinal Health's ROIC?
Cardinal Health's return on invested capital was 83.7% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Cardinal Health have?
Cardinal Health had total debt of $9.9 billion at the end of fiscal 2026 and $5.1 billion of net debt (1.46 times EBITDA).
What is Cardinal Health's dividend yield?
Cardinal Health's forward dividend yield is 0.81%. Cardinal Health paid $491.0 million in dividends in fiscal 2026 ($2.07 per share), a payout ratio of 28.6%.
Does Cardinal Health buy back its shares?
Yes. Cardinal Health spent $1.4 billion on net share repurchases in fiscal 2026 Shares outstanding changed −2.1% over the year, to 237.0M..
What is Cardinal Health's free cash flow yield?
Cardinal Health generated $4.5 billion of free cash flow in fiscal 2026, a free cash flow yield of 8.0% on its market value at year-end ($56.3 billion).
What is Cardinal Health's current ratio?
Cardinal Health's current ratio was 0.88 at the end of fiscal 2026: current assets were 0.88 times current liabilities.